comparemela.com

Latest Breaking News On - Renal division at brigham - Page 1 : comparemela.com

Common Medications for Diabetic Kidney Disease May Be Linked to Increased Risk of Hyperkalemia

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Had a Kidney Stone? This Diet May Help Prevent Another

Investegate |NuCana plc Announcements | NuCana plc: NuCana Appoints Elliott M Levy, M D to its Board of Directors

BioSpace Movers & Shakers, May 21

Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.  AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.

Omega Therapeutics Strengthens Board of Directors with Appointment of R&D Veteran Elliott M Levy, M D

Share this article Share this article CAMBRIDGE, Mass., May 20, 2021 /PRNewswire/ Omega Therapeutics, Inc. ( Omega ), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines, today announced the appointment of Elliott M. Levy, M.D., to its Board of Directors. Dr. Levy is an industry veteran with over 20 years of research and development experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb. Elliott s extensive leadership experience in spearheading research and development strategy and operations at all stages of clinical development is a valuable addition to our team as we focus our efforts on further expanding the potential of our OMEGA platform across a broad array of diseases. Through his professional career at major pharmaceutical companies, Ellio

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.